Kezar Life Sciences Announces Upcoming Presentation of Topline Results from PORTOLA Phase 2a Trial for Autoimmune Hepatitis
South San Francisco, CA – Kezar Life Sciences, a pioneering biotechnology company, is set to unveil the results of its PORTOLA Phase 2a clinical trial investigating the potential of zetomipzomib as a treatment for autoimmune hepatitis (AIH). This groundbreaking event is scheduled for Tuesday, March 25, 2025, at 8:00 a.m. Eastern Time.
About Kezar Life Sciences and Zetomipzomib
Kezar Life Sciences, Inc. (Nasdaq: KZR) is a clinical-stage biotechnology company specializing in the development of innovative small molecule therapeutics to address unmet needs in immune-mediated diseases. Zetomipzomib is one of the company’s lead compounds, which functions by selectively inhibiting a specific protein, Bruton’s tyrosine kinase (BTK), that plays a crucial role in the immune response. Preclinical studies have shown that zetomipzomib may be effective in treating AIH by modulating the immune system and reducing inflammation in the liver.
PORTOLA Phase 2a Trial Design and Objectives
The PORTOLA Phase 2a trial is a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of zetomipzomib in patients with AIH. The trial enrolled 50 participants, who were randomly assigned to receive either zetomipzomib or a placebo in addition to standard-of-care immunosuppressive therapy. The primary endpoints of the study include changes in ALT (alanine transaminase) and AST (aspartate transaminase) levels, which are markers of liver injury and inflammation, as well as safety and tolerability assessments.
Expected Impact on Patients and the World
If the results of the PORTOLA Phase 2a trial demonstrate the safety and efficacy of zetomipzomib in treating AIH, it could pave the way for a new, more effective treatment option for the millions of people living with this chronic and debilitating condition. AIH is an autoimmune disease characterized by inflammation and damage to the liver, leading to symptoms such as fatigue, abdominal pain, and jaundice. Current treatments include corticosteroids and other immunosuppressive drugs, which can have significant side effects and limit long-term use. Zetomipzomib’s targeted mechanism of action could potentially offer a more effective and safer treatment option for patients with AIH.
Furthermore, the successful development of zetomipzomib for AIH could serve as a foundation for exploring its potential in other immune-mediated diseases, expanding the company’s pipeline and contributing to the overall advancement of the biotech industry.
Conclusion
On March 25, 2025, Kezar Life Sciences will reveal the topline results of the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of autoimmune hepatitis. This groundbreaking study has the potential to bring a more effective and safer treatment option to the millions of people living with this chronic condition and open new avenues for exploring the therapeutic potential of zetomipzomib in other immune-mediated diseases. Stay tuned for further updates on this exciting development in the world of biotechnology.
- Kezar Life Sciences to present PORTOLA Phase 2a trial results for zetomipzomib in AIH treatment on March 25, 2025
- Zetomipzomib is a clinical-stage small molecule therapeutic that selectively inhibits Bruton’s tyrosine kinase (BTK)
- PORTOLA Phase 2a trial is a randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, and efficacy of zetomipzomib in AIH patients
- Successful trial results could lead to a new, more effective and safer treatment option for AIH patients
- Potential expansion of zetomipzomib’s therapeutic potential in other immune-mediated diseases
